ProShare Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-11,069
| Closed | -$11.8K | – | 1979 |
|
|
2023
Q3 | $11.8K | Buy |
11,069
+72
| +0.7% | +$77 | ﹤0.01% | 1802 |
|
|
2023
Q2 | $28.5K | Buy |
10,997
+550
| +5% | +$1.42K | ﹤0.01% | 1818 |
|
|
2023
Q1 | $42.6K | Sell |
10,447
-1,514
| -13% | -$6.18K | ﹤0.01% | 1684 |
|
|
2022
Q4 | $60K | Buy |
11,961
+823
| +7% | +$4.13K | ﹤0.01% | 1720 |
|
|
2022
Q3 | $145K | Buy |
11,138
+562
| +5% | +$7.32K | ﹤0.01% | 1473 |
|
|
2022
Q2 | $136K | Sell |
10,576
-3,373
| -24% | -$43.4K | ﹤0.01% | 1556 |
|
|
2022
Q1 | $213K | Sell |
13,949
-3,881
| -22% | -$59.3K | ﹤0.01% | 1851 |
|
|
2021
Q4 | $316K | Sell |
17,830
-2,732
| -13% | -$48.4K | ﹤0.01% | 1754 |
|
|
2021
Q3 | $432K | Sell |
20,562
-1,450
| -7% | -$30.5K | ﹤0.01% | 1298 |
|
|
2021
Q2 | $434K | Buy |
22,012
+4,962
| +29% | +$97.8K | ﹤0.01% | 1632 |
|
|
2021
Q1 | $496K | Buy |
17,050
+1,119
| +7% | +$32.6K | ﹤0.01% | 1445 |
|
|
2020
Q4 | $483K | Buy |
15,931
+1,918
| +14% | +$58.2K | ﹤0.01% | 1298 |
|
|
2020
Q3 | $223K | Sell |
14,013
-68
| -0.5% | -$1.08K | ﹤0.01% | 1360 |
|
|
2020
Q2 | $278K | Buy |
14,081
+3,470
| +33% | +$68.5K | ﹤0.01% | 1268 |
|
|
2020
Q1 | $131K | Sell |
10,611
-7,112
| -40% | -$87.8K | ﹤0.01% | 1054 |
|
|
2019
Q4 | $328K | Buy |
+17,723
| New | +$328K | ﹤0.01% | 1284 |
|